AnGes

AnGes's lead drug is Collategene (beperminogene perplasmid), a plasmid DNA gene therapy encoding hepatocyte growth factor. It received conditional and time-limited approval from Japan's Ministry of Health, Labour and Welfare in 2019 for treating critical limb ischemia, a severe peripheral artery disease that can lead to amputation. It remains the first gene therapy product approved in Japan.

EmendoBio was spun out of AnGes and listed on the Tokyo Stock Exchange Growth market in December 2021. AnGes transferred its intradermal DNA vaccine for SARS-CoV-2 into EmendoBio, effectively creating a separate public vehicle to finance and develop the pandemic-response program independently of the parent company's core vascular gene therapy business.

AnGes maintains a direct pharmaceutical sales force in Japan calling on vascular surgeons rather than relying fully on a larger pharmaceutical partner. The company distributes the drug through a targeted network of hospital pharmacies equipped to handle gene therapy logistics, a go-it-alone model that gives it end-to-end control over launch execution but limits reach versus a partnered commercial strategy.

AnGes is a publicly traded company listed on the Tokyo Stock Exchange Mothers market (now part of the Growth market segment) since 2002. The group structure includes wholly owned subsidiaries handling clinical development and sales, plus the separately listed EmendoBio, making AnGes more of a platform holding company for genetic medicine assets than a classic single-asset biotech.

AnGes is an operating biopharmaceutical company, not an investment firm, so capital allocation decisions — pipeline prioritization, partnership terms, subsidiary listings — rest with President and CEO Ei Yamada and the board of directors. Institutional investors access AnGes as a public equity holding rather than as an alternative investment fund.